Vertex's chief executive, Reshma Kewalramani. Vertex Pharma's bid to expand beyond its cystic fibrosis franchise has taken a big step forward, thanks to positive late-stage clinical data for ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Vertex Pharmaceuticals' largest ...

I’ve had my Shark Rocket HV301 for seven years, and it has never let me down on hardwood floors, high-pile area rugs, or tile. Recently, I moved into a larger apartment with more furniture, more ...

Vertex Pharmaceuticals is the leader in cystic fibrosis treatment. The company has also expanded into other areas in recent years, winning approval for two new drugs. Vertex is the global leader in ...

Cystic fibrosis (CF) specialist Vertex is tracking two newer launches that speak to its efforts to expand its prowess beyond those roots. Despite mixed early results for those rollouts so far, the ...

BOSTON, February 12, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Vertex Pharmaceuticals (NasdaqGS:VRTX) entered an agreement with WuXi Biologics to ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex executives warned that Casgevy, its ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock is falling on Tuesday after the company’s pain data overshadowed strong second-quarter earnings. See real-time price for VRTX stock here. On Monday, the ...

A Vertex Pharmaceuticals drug viewed as a successor to a non-opioid pill that won a landmark FDA approval earlier this year has failed a mid-stage clinical trial, dealing a setback to the company’s ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...